Alba Therapeutics is recruiting people with celiac disease to participate in a clinical research study to test a new investigational medication.
Participants must be:
- Diagnosed with celiac disease by biopsy or capsule endoscopy.
- Between 18 and 75.
- Been attempting to follow a gluten-free diet for 12 months or longer.
If you meet these initial criteria and are interested in learning more about the study, check the online pre-screener at http://www.celiactrial.com/Home.aspx
Be aware
As with any important health decision, it is important that you understand fully what is involved before deciding to take part in a clinical study. Make sure you read all of the information you are given, and ask a member of the study team if anything is not clear. You may also want to talk to your primary care physician or family doctor about whether taking part is right for you. The study team will be able to talk to you about what other treatment options are available to you.
Here’s a story from CCA President Brian Benwell about his experience spreading the news about celiac disease and oral health.
“Last year I pointed my dentist to some information about the link between oral health and celiac disease: http://www.jcda.ca/article/b39/. I guess he read it, because at some point later in the year he had encouraged another patient to consult his family doctor about CD, based on the health of his mouth. This patient’s family doctor was skeptical, but ordered the tests. A diagnosis of CD was the eventual outcome. My dentist was thrilled with the opportunity to participate in a wider range of delivering good health care, and he thanked me for the tip.”
The CCA now has a printable version of the dental facts sheet in brochure and downloadable form that anyone can download: http://bit.ly/cca_dental. Take it to your dentist. We look forward to hearing repeats of Brian’s story from across the country. Please let us know how it all works.
Look for more items about celiac disease and oral and dental health through out the month here on our blog, on Facebook, and Twitter.